<DOC>
	<DOCNO>NCT03078907</DOCNO>
	<brief_summary>The primary objective study evaluate effect selexipag physical activity patient pulmonary arterial hypertension ( PAH ) daily life , use wearable wrist device ( actigraph ) . The actigraph collect data daily life physical activity patient 's real environment . In addition , PAH symptoms impact assess use electronic patient report outcome measure patient 's real environment . Patients assign randomly either selexipag placebo .</brief_summary>
	<brief_title>Effect Selexipag Daily Life Physical Activity Patients With Pulmonary Arterial Hypertension .</brief_title>
	<detailed_description>This study design exploratory purpose generate hypotheses new endpoint</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Male female 18 75 year old inclusive . Women childbearing potential must negative serum pregnancy test plan visit use acceptable method birth control screen 30 day study treatment discontinuation . Symptomatic pulmonary arterial hypertension ( PAH ) belong one follow subgroup : Idiopathic Heritable Drug toxin induce Associated one following : connective tissue disease ; HIV infection ; correct simple congenital heart disease . With follow hemodynamic characteristic assess right heart catheterization ( RHC ) prior randomization : Mean pulmonary artery pressure ( mPAP ) ≥ 25 mmHg Pulmonary vascular resistance ( PVR ) ≥ 240 dyn•sec/cm5 ( 3 Wood Units ) Pulmonary artery wedge pressure ( PCWP ) leave ventricular enddiastolic pressure ( LVEDP ) ≤ 15 mmHg . Treatment endothelin receptor antagonist ( ERA ) least 90 day stable dose 30 day prior randomization . If ERA give combination phosphodiesterase5 ( PDE5 ) inhibitor soluble guanylate cyclase ( sGC ) stimulator , treatment must ongoing least 90 day stable dose 30 day prior randomization . WHO functional class ( FC ) II III randomization 6minute walk distance ( 6MWD ) ≥ 100 screening . Ability walk without walk aid . Valid baseline data daily life physical activity ( DLPA ) PAHSYMPACT® . Patients PAHspecific monotherapy target nitric oxide pathway ( i.e . PDE5 inhibitor sGC stimulator ) . Patients treat prostacyclin , prostacyclin analog selexipag within 3 month prior screen . Any hospitalization last 30 day prior screen . Severe coronary heart disease unstable angina . Documented severe hepatic impairment severe renal insufficiency screen . Participation cardiopulmonary rehabilitation program base exercise training within 8 week prior screen Any factor condition likely affect full participation study compliance protocol ( adherence protocol mandate procedure ) , judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>daily life</keyword>
	<keyword>physical activity</keyword>
	<keyword>actigraphy</keyword>
	<keyword>PAH-SYMPACT</keyword>
</DOC>